Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb Looks To Feed Oncology Pipeline With New Protein Class

This article was originally published in The Pink Sheet Daily

Executive Summary

Discovery and development deal could be worth up to $1.3 billion for Waltham, Mass.-based Adnexus.
Advertisement

Related Content

Adnexus Buy Aimed At Enhancing Bristol’s Transformation To Biopharma Business
Adnexus Buy Aimed At Enhancing Bristol’s Transformation To Biopharma Business
FDA Grants Satraplatin Priority Review
FDA Grants Satraplatin Priority Review
Schering-Plough Expands Antibody Collaboration With Xoma
Schering-Plough Expands Antibody Collaboration With Xoma
Merck KGaA Follows Pfizer With Archemix Deal For Aptamer-Based Therapeutics

Topics

Advertisement
UsernamePublicRestriction

Register

PS065679

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel